<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04270747</url>
  </required_header>
  <id_info>
    <org_study_id>20170542</org_study_id>
    <secondary_id>2019-002503-17</secondary_id>
    <nct_id>NCT04270747</nct_id>
  </id_info>
  <brief_title>A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]</brief_title>
  <official_title>A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects With Neovascular Age-related Macular Degeneration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of ABP 938 versus Aflibercept&#xD;
      (Eylea®) in the treatment of neovascular age-related macular degeneration. Subjects will be&#xD;
      randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938 (Treatment Group&#xD;
      A) or aflibercept (Treatment Group B) administered by intravitreal (IVT) injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 566 subjects will be randomized in approximately 126 global sites.&#xD;
&#xD;
      This study consists of a screening period of up to 4 weeks, after which subjects will receive&#xD;
      investigational product for 48 weeks, followed by a safety follow-up period to week 52, for a&#xD;
      total study duration of up to 56 weeks.&#xD;
&#xD;
      Subjects will be randomized in a masked 1:1 ratio to receive 2 mg (0.05 mL) of either ABP 938&#xD;
      (Treatment Group A) or aflibercept (Treatment Group B) administered by IVT injection.&#xD;
&#xD;
      At week 8, subjects will be assessed for the primary endpoint. The primary endpoint is the&#xD;
      change in Best Corrected Visual Acuity (BCVA) as measured by Early Treatment Diabetic&#xD;
      Retinopathy Study (ETDRS) letter score from baseline to week 8, in order to assess the&#xD;
      efficacy of ABP 938 compared to aflibercept.&#xD;
&#xD;
      Subjects will then be re-randomized at week 16 in a masked fashion such that:&#xD;
&#xD;
        -  Subjects initially randomized to ABP 938 (Treatment Group A) will continue to receive&#xD;
           ABP 938 by IVT injection every 8 weeks from week 16 until week 48&#xD;
&#xD;
        -  Subjects initially randomized to aflibercept (Treatment Group B) will be re-randomized&#xD;
           in a 1:1 ratio to either continue on aflibercept (Treatment Group B1) or transition to&#xD;
           ABP 938 (Treatment Group B2) by IVT injection every 8 weeks from week 16 until week 48&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2020</start_date>
  <completion_date type="Anticipated">December 8, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 17, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>The study is double-masked; therefore, the investigators, study personnel, and the study subjects will remain masked to treatment allocation. Unmasking is only allowed in the case of an emergency, when knowledge of the investigational product is essential for the clinical management of the subject.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>At week 8</time_frame>
    <description>Change from Baseline in BCVA as measured by Early Treatment Diabetic Retinopathy Study (ETDRS) letter score at week 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ETDRS letter score at week 52 maintaining vision lost fewer than 15 letters</measure>
    <time_frame>At week 52</time_frame>
    <description>Proportion of subjects who maintained vision at week 52, where a subject was classified as maintaining vision if he/she lost fewer than 15 letters in ETDRS letter score compared to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in BCVA</measure>
    <time_frame>At screening, day 1, week 4, week 8, week 16, week 24, week 32, week 40, week 48 and week 52</time_frame>
    <description>Change from Baseline in BCVA as measured by ETDRS letter score over the study duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in ETDRS letter score at week 8 and week 52</measure>
    <time_frame>At week 8 and week 52</time_frame>
    <description>Proportion of subjects who gained at least 10 letters of vision at week 8 and proportion of subjects who gained at least 15 letters of vision at week 52 as compared to Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Choroidal Neovascularization (CNV) area</measure>
    <time_frame>At screening, day 1, week 4, week 8, week 16, week 24, week 32, week 40, week 48 and week 52</time_frame>
    <description>Change from Baseline in CNV area as measured by Fluorescein Angiography (FA) over the study duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Central Subfield Thickness (CST)</measure>
    <time_frame>At screening, day 1, week 4, week 8, week 16, week 24, week 32, week 40, week 48 and week 52</time_frame>
    <description>Change from Baseline in CST as measured by spectral domain optical coherence tomography (SD-OCT) over the study duration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with incidence of Antidrug Antibodies (ADA)</measure>
    <time_frame>At day 1, week 8, week 16, week 24, week 40 and week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with treatment-emergent adverse events, adverse events of interest (EOIs), and serious adverse events</measure>
    <time_frame>Upto 56 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">566</enrollment>
  <condition>Neovascular (Wet) Age-related Macular Degeneration (AMD)</condition>
  <arm_group>
    <arm_group_label>ABP 938-Treatment Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive 2 mg (0.05 mL) of ABP 938 by intravitreal (IVT) injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8) and every 8 weeks from week 16 until week 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept-Treatment Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will receive 2 mg (0.05 mL) of aflibercept (Treatment Group B) by intravitreal (IVT) injection every 4 weeks for the first 3 doses (ie, baseline/day 1, week 4, and week 8).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept-Treatment Group B1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects initially randomized to aflibercept (Treatment Group B) will be re-randomized to receive aflibercept by IVT injection every 8 weeks from week 16 until week 48</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABP 938-Treatment group B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects initially randomized to aflibercept (Treatment Group B) will be re-randomized to receive ABP 938 by IVT injection every 8 weeks from week 16 until week 48</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABP 938</intervention_name>
    <description>Subject will receive ABP 938 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks</description>
    <arm_group_label>ABP 938-Treatment Group A</arm_group_label>
    <arm_group_label>ABP 938-Treatment group B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Subject will receive aflibercept 2 mg (0.05 mL) IVT injection every 4 weeks for the first 3 doses, followed by once every 8 weeks</description>
    <arm_group_label>Aflibercept-Treatment Group B</arm_group_label>
    <arm_group_label>Aflibercept-Treatment Group B1</arm_group_label>
    <other_name>Eylea®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects or their legally authorized representative must sign an Institutional Review&#xD;
             Board/Independent Ethics Committee approved informed consent form before any&#xD;
             study-specific procedures&#xD;
&#xD;
          -  Men or women ≥ 50 years old&#xD;
&#xD;
          -  Subjects must be diagnosed with neovascular (wet) AMD in the study eye&#xD;
&#xD;
          -  Active treatment naïve subfoveal CNV lesions secondary to neovascular (wet) AMD&#xD;
             including juxtafoveal lesions that affect the fovea as confirmed with SD OCT, FA&#xD;
             and/or Fundus Photography (FP) in the study eye&#xD;
&#xD;
          -  BCVA between 73 and 34 letters, inclusive, in the study eye using ETDRS testing&#xD;
&#xD;
          -  Presence of intra and/or subretinal fluid as identified by SD-OCT attributable to&#xD;
             active CNV in the study eye&#xD;
&#xD;
          -  Central retinal thickness of &gt; 270µm in the study eye as measured by the machine,&#xD;
             calculated average thickness in the central 1 mm subfield (CST) by SD-OCT at screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects are excluded if they meet any of the following criteria in the study eye:&#xD;
&#xD;
          -  Total lesion size &gt; 12 disc areas (30.5 mm^2, including blood, scars, and&#xD;
             neovascularization) in the study eye&#xD;
&#xD;
          -  Active CNV area (classic plus occult components) that is &lt; 50% of the total lesion&#xD;
             area in the study eye&#xD;
&#xD;
          -  Scar, fibrosis, or atrophy involving the center of the fovea in the study eye&#xD;
&#xD;
          -  Presence of retinal pigment epithelium tears or rips involving the macula in the study&#xD;
             eye&#xD;
&#xD;
          -  History of any vitreous hemorrhage within 4 weeks before randomization in the study&#xD;
             eye&#xD;
&#xD;
          -  Presence of other causes of CNV, including pathologic myopia (spherical equivalent of&#xD;
             8 diopters or more negative or axial length of 25 mm or more), ocular histoplasmosis&#xD;
             syndrome, angioid streaks, choroidal rupture, or multifocal choroiditis in the study&#xD;
             eye&#xD;
&#xD;
          -  Prior vitrectomy or laser surgery of the macula (including photodynamic therapy or&#xD;
             focal laser photocoagulation) in the study eye&#xD;
&#xD;
          -  History of retinal detachment in the study eye&#xD;
&#xD;
          -  Any history of macular hole of stage 2 and above in the study eye&#xD;
&#xD;
          -  Any macular pathology that might limit vision i.e., Vitreomacular traction or&#xD;
             significant epiretinal membrane in the study eye&#xD;
&#xD;
          -  Any intraocular or periocular surgery within 3 months before randomization on the&#xD;
             study eye, except lid surgery, which may not have taken place within 4 weeks before&#xD;
             randomization, as long as it is unlikely to interfere with the injection&#xD;
&#xD;
          -  Prior trabeculectomy or other filtration surgery in the study eye&#xD;
&#xD;
          -  Uncontrolled glaucoma (defined as intraocular pressure ≥ 25 mmHg despite treatment&#xD;
             with antiglaucoma medication) in the study eye&#xD;
&#xD;
          -  Aphakia or pseudophakia with complete absence of posterior capsule (unless it occurred&#xD;
             as a result of a yttrium aluminum garnet [YAG] posterior capsulotomy) in the study eye&#xD;
&#xD;
          -  Previous therapeutic radiation in the region of the study eye&#xD;
&#xD;
          -  History of corneal transplant or corneal dystrophy in the study eye&#xD;
&#xD;
          -  Significant media opacities, including cataract, which might interfere with visual&#xD;
             acuity or assessment of safety, in the study eye&#xD;
&#xD;
          -  Any concurrent intraocular condition other than neovascular (wet) AMD in the study eye&#xD;
             that, in the opinion of the investigator, requires planned medical or surgical&#xD;
             intervention during the study or increases the risk to the subject beyond what is&#xD;
             expected from standard procedures of intraocular injection, or which otherwise may&#xD;
             interfere with the injection procedure or with evaluation of efficacy or safety&#xD;
&#xD;
        Subjects are excluded if they meet any of the following criteria in either eye:&#xD;
&#xD;
          -  History or clinical evidence of uveitis, diabetic retinopathy, diabetic macular edema,&#xD;
             or any other vascular disease affecting the retina, other than neovascular (wet) AMD&#xD;
&#xD;
          -  Active intraocular inflammation or active or suspected ocular or periocular infection,&#xD;
             within 2 weeks before randomization&#xD;
&#xD;
          -  Active scleritis or episcleritis or presence of scleromalacia&#xD;
&#xD;
        Other Medical Conditions&#xD;
&#xD;
        • Active extraocular infection or history of extraocular infections as follows: A. any&#xD;
        active infection for which systemic anti-infectives were used within 4 weeks before&#xD;
        randomization B. recurrent or chronic infections or other active infection that, in the&#xD;
        opinion of the investigator, might cause this study to be detrimental to the subject&#xD;
&#xD;
          -  Acute coronary event or stroke within 3 months before randomization&#xD;
&#xD;
          -  Uncontrolled, clinically significant systemic disease such as diabetes mellitus,&#xD;
             hypertension, cardiovascular disease including moderate to severe heart failure (New&#xD;
             York Heart Association class III/IV), renal disease, or liver disease&#xD;
&#xD;
          -  Malignancy within 5 years EXCEPT treated and considered cured cutaneous squamous or&#xD;
             basal cell carcinoma, in situ cervical cancer, OR in situ breast ductal carcinoma&#xD;
&#xD;
        Washouts and Nonpermitted Treatments&#xD;
&#xD;
          -  Any prior ocular or systemic treatment, including another investigational product or&#xD;
             surgery for neovascular (wet) AMD (including anti vascular endothelial growth factor&#xD;
             [VEGF] therapy) in the study eye, except dietary supplements or vitamins&#xD;
&#xD;
          -  Any ocular or systemic treatment including another investigational product or surgery&#xD;
             for neovascular (wet) AMD (including anti VEGF therapy) in the fellow eye, within 30&#xD;
             days before randomization, except dietary supplements or vitamins&#xD;
&#xD;
          -  Prior systemic anti-VEGF treatment as follows:&#xD;
&#xD;
          -  Investigational or approved anti-VEGF therapy systemically within 3 months before&#xD;
             randomization&#xD;
&#xD;
          -  Aflibercept, ziv-aflibercept, or a biosimilar of aflibercept/ziv-aflibercept&#xD;
             systemically at any time&#xD;
&#xD;
          -  Any IVT therapy, including adrenocorticotropic hormone, in the study or fellow eye, or&#xD;
             intramuscular or intravenous corticosteroids within 4 weeks before randomization. The&#xD;
             use of long-acting steroids, either systemically or intraocularly, in the 3 months&#xD;
             before randomization&#xD;
&#xD;
          -  Currently receiving treatment with another investigational device or study drug, or&#xD;
             less than 30 days or 5 half-lives (whichever is longer) since ending treatment on&#xD;
             another investigational device or drug study(ies). Other investigational procedures&#xD;
             while participating in this study are excluded&#xD;
&#xD;
        General&#xD;
&#xD;
          -  For women: pregnant or breast feeding, or planning to become pregnant while enrolled&#xD;
             in the study and for 3 months after the last dose of investigational product&#xD;
&#xD;
          -  Sexually active subjects and their partners who are of childbearing potential (ie,&#xD;
             neither surgically sterile nor postmenopausal) and not agreeing to use adequate&#xD;
             contraception (eg, true abstinence, sterilization, birth control pills, Depo Provera&#xD;
             injections, contraceptive implants, or other effective methods) while on study and for&#xD;
             3 months after the last dose of study drug. Male subjects must agree not to donate&#xD;
             sperm during study and for 3 months following treatment with test article or until the&#xD;
             scheduled end of the study (whichever is longer)&#xD;
&#xD;
          -  Allergy or hypersensitivity to investigational product, to any of the excipients of&#xD;
             ABP 938 or aflibercept, or to other study-related procedures/medications (eg,&#xD;
             anesthesia, antiseptic, fluorescein dye)&#xD;
&#xD;
          -  History or evidence of any other clinically significant disorder, condition, or&#xD;
             disease (with the exception of those outlined above) that, in the opinion of the&#xD;
             investigator or Amgen physician, if consulted, would pose a risk to subject safety or&#xD;
             interfere with the study evaluation, procedures, or completion&#xD;
&#xD;
          -  Subject likely to not be available to complete all protocol-required study visits or&#xD;
             procedures, and/or to comply with all required study procedures (eg, Clinical Outcome&#xD;
             Assessments) to the best of the subject and investigator's knowledge&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Associated Retina Consultants, Ltd. - Research</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Orange County</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCSD Shiley Eye Institute, Jacobs Retina Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jules Stein Eye Institute, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-7000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southern California Desert Retina Consultants</name>
      <address>
        <city>Palm Desert</city>
        <state>California</state>
        <zip>92211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants San Diego - La Jolla</name>
      <address>
        <city>Poway</city>
        <state>California</state>
        <zip>92064</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Southern California</name>
      <address>
        <city>Redlands</city>
        <state>California</state>
        <zip>92374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants Medical Group, Inc.</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Orange County Retina Medical Group</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Miramar Eye Specialists</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003-2999</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Colorado Retina Associates</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Group of New England</name>
      <address>
        <city>Waterford</city>
        <state>Connecticut</state>
        <zip>06385</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Florida Retina Consultants</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medeye Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Retina and Macular Disease</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Georgia Retina, P.C.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Associates IL</name>
      <address>
        <city>Elmhurst</city>
        <state>Illinois</state>
        <zip>60126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sabates Eye Center</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Associates New Orleans</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Retina Care Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The National Retina Institute, A Katzen Eye Group Practice</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Specialty Eye Institute</name>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <zip>49202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404-3846</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retinal &amp; Ophthalmic Consultants, PC</name>
      <address>
        <city>Northfield</city>
        <state>New Jersey</state>
        <zip>08225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vision Research Center Eye Associates of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Surgeons of Central NY, PC</name>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Macula Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose &amp; Throat Associates, P.A.</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eye Care Specialists</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of the Capital Region - Ophthalmology</name>
      <address>
        <city>West Mifflin</city>
        <state>Pennsylvania</state>
        <zip>15122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charleston Neuroscience Institute</name>
      <address>
        <city>Ladson</city>
        <state>South Carolina</state>
        <zip>29456</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute - Ophthalmology</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Research Institute of Texas</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <zip>76012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Texas Research Centers</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Premiere Retina Specialists</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <zip>79706</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Retina Associates of South Texas, P.A. - San Antonio - Med</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240-1375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Strategic Clinical Research</name>
      <address>
        <city>Willow Park</city>
        <state>Texas</state>
        <zip>76087</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Canadian Centre for Advanced Eye Therapeutics Inc</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L4W 1W9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Eye Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinique d'ophtalmologie des laurentides</name>
      <address>
        <city>Boisbriand</city>
        <state>Quebec</state>
        <zip>J7H 0E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ocni klinika Pardubice</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FN Kralovske Vinohrady</name>
      <address>
        <city>Praha 10</city>
        <zip>100 34</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vseobecna fakultni nemocnice v Praze</name>
      <address>
        <city>Praha 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Axon Clinical, s.r.o.</name>
      <address>
        <city>Praha 5</city>
        <zip>150 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krajska zdravotni, a.s. Masarykova nemocnice v Usti n/ Labem</name>
      <address>
        <city>Usti nad Labem</city>
        <state>Ústí Nad Labem</state>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>East Tallinn Central Hospital - Eye Clinic</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oü Dr Kai Noor Silmakabinet</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>11412</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eye Clinic of Dr. Krista Turman</name>
      <address>
        <city>Tallinn</city>
        <state>Harjumaa</state>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eye Clinic of Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <state>Niedersachsen</state>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Franziskus Hospital Münster</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Charité Berlin-Campus Benjamin Franklin (CBF)</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong - Department of Ophthalmology</name>
      <address>
        <city>Aberdeen</city>
        <zip>000000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital - Department of Ophthalmology and Visual Sciences</name>
      <address>
        <city>Shatin, New Territories</city>
        <zip>000000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ganglion Orvosi Központ</name>
      <address>
        <city>Pécs</city>
        <state>Baranya</state>
        <zip>7621</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpo</name>
      <address>
        <city>Szeged</city>
        <state>Csongrád</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Központ - Szemklinika</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdú-Bihar</state>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Péterfy Kórház-Rendelintézet és Manninger Jen Országos Traumatológiai Intézet - Szemészeti Osztály</name>
      <address>
        <city>Budapest</city>
        <zip>1076</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bajcsy-Zsilinszky Kórház és Rendelintézet</name>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Budapest Retina Associates</name>
      <address>
        <city>Budapest</city>
        <zip>1133</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MH Egészségügyi Központ</name>
      <address>
        <city>Budapest</city>
        <zip>H-1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <zip>H-1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center</name>
      <address>
        <city>Be er-Sheva</city>
        <state>HaDarom</state>
        <zip>8410101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <state>HaDarom</state>
        <zip>3104802</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meir Medical Center</name>
      <address>
        <city>Kfar Saba</city>
        <state>HaMerkaz</state>
        <zip>4428164</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center</name>
      <address>
        <city>Rehovot</city>
        <zip>7610001</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh Medical Center</name>
      <address>
        <city>Zerifin</city>
        <zip>7030000</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fondazione PTV Policlinico Tor Vergata, UNIT Patologie Retiniche</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UOC Oculistica Fondazione PU A.Gemelli IRCCS Un.Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>&quot;Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, UO Oculistica Dipartimento di Chirurgia&quot;</name>
      <address>
        <city>Milano (MI)</city>
        <state>Milano</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Perugia, Ospedale Santa Maria della Misericordia, Clinica Oculistica</name>
      <address>
        <city>Perugia</city>
        <state>Umbria</state>
        <zip>06129</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UO Oftalmologia Ciardella Pol. S.Orsola Malpighi AOU di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya University Hospital</name>
      <address>
        <city>Nagoya</city>
        <state>Aiti</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagoya City University Hospital - Ophthalmology</name>
      <address>
        <city>Nagoya</city>
        <state>Aiti</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asahikawa Medical University Hospital</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaidô</state>
        <zip>078-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fukushima Medical University Hospital - Ophthalmology</name>
      <address>
        <city>Fukushima</city>
        <state>Hukusima</state>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Hospital - Ophthalmology</name>
      <address>
        <city>Kagoshima</city>
        <state>Kagosima</state>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nihon University Hospital - Ophthalmology</name>
      <address>
        <city>Tokyo</city>
        <state>Tôkyô</state>
        <zip>101-8309</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Yamanashi Hospital</name>
      <address>
        <city>Chuo</city>
        <state>Yamanasi</state>
        <zip>409-3898</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akita University Hospital - Ophthalmology</name>
      <address>
        <city>Akita</city>
        <zip>010-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital - Ophthalmology</name>
      <address>
        <city>Nagasaki</city>
        <zip>852-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kansai Medical University Hospital - Ophthalmology</name>
      <address>
        <city>Hirakata</city>
        <state>Ôsaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital - Department of Ophthalmology</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center - Ophthalmology</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital - Neurology</name>
      <address>
        <city>Seoul</city>
        <state>Seoul Teugbyeolsi</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital - Ophthalmology</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>P.Stradina Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <state>Rga</state>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Signes Ozolinas Doctor Praxis in Ophthalmology</name>
      <address>
        <city>Jelgava</city>
        <zip>LV- 3001</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klaipedos Universitetine ligoniene</name>
      <address>
        <city>Klaipeda</city>
        <state>Klaipdos Apskritis</state>
        <zip>LT-92288</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vilniaus Universiteto Ligonines Santariskiu Klinikos (VULSK)</name>
      <address>
        <city>Vilnius</city>
        <state>Vilniaus Apskritis</state>
        <zip>8661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Asociación para Evitar la Ceguera en México I.A.P.</name>
      <address>
        <city>México DF</city>
        <state>Distrito Federal</state>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Medico Zambrano Hellion</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64710</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Retina Medica y Quirurgica S.C.</name>
      <address>
        <city>Zapopan</city>
        <zip>45116</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Profesorskie Centrum Okulistyki OKULISTYKA OPTIMUM</name>
      <address>
        <city>Gdansk</city>
        <state>Pomorskie</state>
        <zip>80-809</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Szpital Sw. Wojciecha</name>
      <address>
        <city>Poznan</city>
        <state>Wielkopolskie</state>
        <zip>61-144</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne PROMED</name>
      <address>
        <city>Krakow</city>
        <zip>31-411</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Diagnostyki i Mikrochirurgii oka Lens Klinika okulistyczna</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-424</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne UNO-MED</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinika Okulistyczna &quot;Jasne Blonia&quot;</name>
      <address>
        <city>Lodz</city>
        <state>Ódzkie</state>
        <zip>91-134</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univerzitna nemocnica Bratislava</name>
      <address>
        <city>Bratislava</city>
        <state>Bratislavský Kraj</state>
        <zip>851 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica s poliklinikou Zilina</name>
      <address>
        <city>Zilina</city>
        <state>Ilinský Kraj</state>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fakultna nemocnica Trencin</name>
      <address>
        <city>Trencin</city>
        <state>Treniansky Kraj</state>
        <zip>911 71</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Bellvitge</name>
      <address>
        <city>LHospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>8097</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>FISABIO - Oftalmología Médica</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

